Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Establishes a process whereby large drug manufacturers, may be penalized for prescription drug price increases where there is no, or inadequate, new evidence to support the price increase.
Introduced
Feb 26, 2025
Last Action
Mar 20, 2025
Session
RI 2025
Sponsors
10 primary · 0 co
03/20/2025 Committee recommended measure be held for further study
03/14/2025 Scheduled for hearing and/or consideration (03/20/2025)
02/26/2025 Introduced, referred to Senate Health and Human Services